This site is intended only for the use of UK Healthcare Professionals


Our formulas are proven to support:

  • Fast and effective symptom management1,2,3,4
  • Healthy growth and development1,2,3,4
  • Reductions in infection rates and medication use1 as well as promoting a positive gut microbiota2,5

About SMA® Althéra® Advance and SMA® Alfamino® Advance

SMA® Althéra® Advance and SMA® Alfamino® Advance are our hypoallergenic formulas, offering first-line formula options for bottle-fed infants with Cow’s Milk Protein Allergy (CMPA). Our range contains a clinically proven blend of two Human Milk Oligosaccharides (HMOs): 2’ fucosyllactose (2’FL) and lacto N neotetraose (LNnT).1,2,5-7

SMA® Althéra® Advance is the most extensively hydrolysed formula (eHF) available in the UK.8 It is suitable for the dietary management of infants with mild to moderate CMPA. Additionally, SMA® Althéra® Advance is:

  • Halal certified.
  • Kosher certified.
  • Suitable for vegetarians.
  • Suitable for children from birth to 3 years of age.

SMA® Alfamino® Advance is our amino acid-based formula (AAF) suitable for the dietary management of infants with severe CMPA, multiple food allergies and other conditions where an AAF is recommended. Backed by data to support normal growth and development4,7*, and with added medium-chain triglycerides (MCTs), structured lipids and a low osmolarity profile to help support digestion and absorption.8-10 SMA® Alfamino® Advance is:

  • Halal certified.
  • Suitable for vegetarians.
  • Suitable for children from birth to 3 years of age.

What are HMOs?

In addition, both formulas support immune health through Nestlé’s unique HMO blend, with benefits including:

  • A gut microbiota profile closer to that of breastfed infants.2,5
  • A significant reduction in the frequency of ear infections.1^
  • A significant reduction in upper respiratory tract infections (42%).1

Watch this video to learn more about HMOs and their benefits. 

Clinically Proven Impact

  • Clinically hypoallergenic: The HMO blends in both SMA® Alfamino® Advance and SMA® Althéra® Advance meet AAP criteria for clinical hypoallergenicity.13
  • Next-generation formulas: Althéra and Alfamino Advance include a unique HMO blend designed to deliver additional clinical benefits for infants with CMPA.1-3
  • Proven symptom relief & growth support: Clinical evidence shows our HMO-containing formulas help alleviate CMPA symptoms and support normal growth.1-4
  • Immune & infection support: Our HMO containing formulas are associated with a potential reduction in respiratory tract infections.1
  • Gut health benefits: Our unique HMO blend has been shown to support improved gut microbial diversity, closer to that of breastfed infants.2,5
  • Inspired by science: Contain 2’-FL and LNnT, structurally identical to those found in breastmilk.  
  • Safe & compliant: Included at 1.0 g/L (2’-FL) and 0.5 g/L (LNnT), meeting regulatory recommendations for safe infant use.

Please note: SMA® Althéra® Advance and SMA® Alfamino® Advance went live on the Drug Tariff on 1st May 2026, and are now listed on the DM+D. Prescription systems will start updating over the coming weeks.

References : 1. Vandenplas Y, et al. Nutrients. 2022;14(3):530. 2. Gold, M.S., et al., Nutrients, 2022.14(11 ): p. 2297. 3. Niggemann B, et al. Pediatr Allergy lmmunol 2008;19(4):348-54. 4. Nowak-Wegrzyn A, et al. Clin Pediatr (Phila). 2015;54(3):264-272. 5. Boulange CL, et al. Int J Mol Sci. 2023;24(14):11422. 6. Puccio G, et al. J Pediatr Gastroenterol Nutr 2017;64(4):624-631. 7. Berger B, et al. mBio 2020;11 (2):e03196-19. 8. Nutten S, et al.Allergy. 2020 Jun;75(6):1446-1449. 9. Vandenplas Y, et al, Pediatr Gastroenterol Hepatol Nutr. 2021 Jul;24(4):1-11 12. 10. Mazzocchi, A.; et al. Nutrients 2018, 10, 567. 11. Bar-Yoseph, F., et al. Prostaglandins Leukot Essent Fatty Acids, 2013. 89(4): p. 139-43. 12. Shaw, V & Lawson, M. Clin Paediatr Dietetics 2007; 3rd ed. Oxford. Blackwell. 13. Nowak-Wegrzyn, A., et al., Nutrients, 2019. 11 (7), 1447.

IMPORTANT NOTICE: 
We believe that breastfeeding is the ideal nutritional start for babies as breast milk provides a balanced diet and protection against illness for a baby. We fully support the World Health Organisation’s recommendation of exclusive breastfeeding for the first six months of life followed by the introduction of adequate nutritious complementary foods along with sustained breastfeeding up to two years of age.
We also recognise that breastfeeding may not be an option due to certain medical conditions. Parents should only feed Infant formula for special medical purposes under supervision of a healthcare professional after full consideration of all feeding options, including breastfeeding. Continued use has to be assessed by the healthcare professional in relation to the baby's progress bearing in mind any social and financial implications for the family. 
Infant formula should always be prepared, used and stored as instructed on the label in order to avoid risks to a baby’s health. 
The following products must be used under medical supervision. SMA® Althéra® Advance is a food for special medical purposes intended for the dietary management of infants with cows’ milk allergy. Suitable as a sole source of nutrition from birth or supplementary feeding from 6 months and up to 3 years of age. SMA® Alfamino® Advance is a food for special medical purposes, for the dietary management of infants with severe cows’ milk allergy, multiple food allergies and other conditions where an amino acid formula is recommended. Suitable as a sole source of nutrition from birth up to 12 months or supplementary feeding from 6 months onwards. Infant formula should always be prepared, used and stored as instructed on the label in order to avoid risks to a baby’s health.